213 related articles for article (PubMed ID: 14687955)
1. Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification.
Sobel BF; Sigmon SC; Walsh SL; Johnson RE; Liebson IA; Nuwayser ES; Kerrigan JH; Bigelow GE
Drug Alcohol Depend; 2004 Jan; 73(1):11-22. PubMed ID: 14687955
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
[TBL] [Abstract][Full Text] [Related]
3. An injection depot formulation of buprenorphine: extended bio-delivery and effects.
Sigmon SC; Moody DE; Nuwayser ES; Bigelow GE
Addiction; 2006 Mar; 101(3):420-32. PubMed ID: 16499515
[TBL] [Abstract][Full Text] [Related]
4. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
6. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence.
White J; Bell J; Saunders JB; Williamson P; Makowska M; Farquharson A; Beebe KL
Drug Alcohol Depend; 2009 Jul; 103(1-2):37-43. PubMed ID: 19403243
[TBL] [Abstract][Full Text] [Related]
7. Opioid detoxification via single 7-day application of a buprenorphine transdermal patch: an open-label evaluation.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Psychopharmacology (Berl); 2008 Jun; 198(2):149-58. PubMed ID: 18327673
[TBL] [Abstract][Full Text] [Related]
8. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers.
Comer SD; Sullivan MA; Vosburg SK; Manubay J; Amass L; Cooper ZD; Saccone P; Kleber HD
Addiction; 2010 Apr; 105(4):709-18. PubMed ID: 20403021
[TBL] [Abstract][Full Text] [Related]
9. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
11. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder.
Haasen C; Linden M; Tiberg F
J Subst Abuse Treat; 2017 Jul; 78():22-29. PubMed ID: 28554599
[TBL] [Abstract][Full Text] [Related]
13. Transferring methadone-maintained outpatients to the buprenorphine sublingual tablet: a preliminary study.
Greenwald MK; Schuh KJ; Stine SM
Am J Addict; 2003; 12(4):365-74. PubMed ID: 14504028
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
15. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids.
Cheskin LJ; Fudala PJ; Johnson RE
Drug Alcohol Depend; 1994 Oct; 36(2):115-21. PubMed ID: 7851278
[TBL] [Abstract][Full Text] [Related]
16. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
[TBL] [Abstract][Full Text] [Related]
17. Transferring methadone-stabilized pregnant patients to buprenorphine using an immediate release morphine transition: an open-label exploratory study.
Jones HE; Suess P; Jasinski DR; Johnson RE
Am J Addict; 2006; 15(1):61-70. PubMed ID: 16449094
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone.
Rosen MI; Wallace EA; McMahon TJ; Pearsall HR; Woods SW; Price LH; Kosten TR
Drug Alcohol Depend; 1994 Apr; 35(2):141-9. PubMed ID: 7519977
[TBL] [Abstract][Full Text] [Related]
19. Effects of high-dose intravenous buprenorphine in experienced opioid abusers.
Umbricht A; Huestis MA; Cone EJ; Preston KL
J Clin Psychopharmacol; 2004 Oct; 24(5):479-87. PubMed ID: 15349002
[TBL] [Abstract][Full Text] [Related]
20. Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder.
Nasser AF; Greenwald MK; Vince B; Fudala PJ; Twumasi-Ankrah P; Liu Y; Jones JP; Heidbreder C
J Clin Psychopharmacol; 2016 Feb; 36(1):18-26. PubMed ID: 26650971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
